Nature GeneticsGeneticsPeer-reviewed journal article
Identification of genetic modifiers of Huntington's disease somatic CAG repeat instability by in vivo CRISPR-Cas9 genome editing
Ricardo Mouro PintoiD, Ryan MurthaiD, António Azevedo, Cameron J. DouglasiD, Marina V. KovalenkoiD, Jessica UlloaiD, Steven Crescenti, Zoe N. Burch, Esaria OliveriD, Maheswaran KesavaniD, Shota ShibataiD, Antonia G. Vitalo, Eduarda Mota‐SilvaiD, Marion J. RiggsiD, Kevin CorreiaiD, Emanuela Elezi, Brigitte Demelo, Jeffrey B. CarrolliD, Tammy GillisiD, James F. GusellaiD, Marcy E. MacDonald, Vanessa Chantal WheeleriD
Abstract
Huntingtons disease (HD), one of >50 inherited repeat expansion disorders (Depienne and Mandel, 2021), is a dominantly-inherited neurodegenerative disease caused by a CAG expansion in HTT (The Huntingtons Disease Collaborative Research Group, 1993). Inherited CAG repeat length is the primary determinant of age of onset, with human genetic studies underscoring that the property driving disease is the CAG length-dependent propensity of the repeat to further expand in brain (Swami et al., 2009; GeM-HD, 2015; Hensman Moss et al., 2017; Ciosi et al., 2019; GeM-HD, 2019; Hong et al., 2021). Routes to slowing somatic CAG expansion therefore hold great promise for disease-modifying therapies. Several DNA repair genes, notably in the mismatch repair (MMR) pathway, modify somatic expansion in HD mouse models (Wheeler and Dion, 2021). To identify novel modifiers of somatic expansion, we have used CRISPR-Cas9 editing in HD knock-in mice to enable in vivo screening of expansion-modifier candidates at scale. This has included testing of HD onset modifier genes emerging from human genome-wide association studies (GWAS), as well as interactions between modifier genes, thereby providing new insight into pathways underlying CAG expansion and potential therapeutic targets.
- organism: mouse
- research focus: drug response / drug discovery
- research focus: benchmarking
- approach: experimental assay
- Citations
- 75
- FWCI
- 26.99
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease reveal shared and tissue-specific effects
Jong‐Min Lee, Zachariah L. McLean, … Richard H. Myers·bioRxiv·Jun 10, 2024
- PMS1 as a target for splice modulation to prevent somatic CAG repeat expansion in Huntington's disease
Zachariah L. McLean, Dadi Gao, … James F. Gusella·Nature CommunicationsPeer-reviewed·Apr 12, 2024
- Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease
Doo Eun Choi, Jun Wan Shin, … Jong‐Min Lee·eLifePeer-reviewed·Dec 19, 2023
- Somatic CRISPR editing of Msh3 mitigates Huntington's disease pathology in mice
Esaria Oliver, Marina V. Kovalenko, … Vanessa Chantal Wheeler·bioRxiv·Jun 10, 2026
- Therapeutic validation of MMR-associated genetic modifiers in a human ex vivo model of Huntington's disease
Ross Ferguson, Robert Goold, … Sarah J. Tabrizi·bioRxiv·Dec 5, 2023
- Interventionally targeting somatic CAG expansions can be a rapid disease-modifying therapeutic avenue: Preclinical evidence.
Terence Gall-Duncan, Sangyoon Y. Ko, … Christopher E. Pearson·bioRxiv·Apr 25, 2025